| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 51.889 | 70.026 | 69.313 | 58.405 | 27.797 | 32.008 | 22.620 | 19.867 |
| Total Income - EUR | - | - | 51.890 | 70.027 | 69.314 | 82.387 | 39.298 | 43.161 | 38.793 | 40.064 |
| Total Expenses - EUR | - | - | 55.827 | 69.043 | 81.012 | 65.220 | 38.600 | 42.088 | 35.522 | 41.980 |
| Gross Profit/Loss - EUR | - | - | -3.937 | 983 | -11.697 | 17.167 | 698 | 1.073 | 3.271 | -1.916 |
| Net Profit/Loss - EUR | - | - | -4.254 | 85 | -12.392 | 16.725 | 425 | 693 | 2.929 | -2.296 |
| Employees | - | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Ganoderma Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 8.024 | 7.909 | 7.717 | 7.571 | 7.403 | 8.732 | 51.311 | 41.805 |
| Current Assets | - | - | 18.660 | 31.663 | 28.007 | 18.259 | 16.796 | 19.197 | 16.096 | 22.796 |
| Inventories | - | - | 6.017 | 15.553 | 17.819 | 8.640 | 13.424 | 9.410 | 10.148 | 14.735 |
| Receivables | - | - | 10.387 | 11.845 | 9.078 | 8.131 | 2.762 | 9.296 | 4.999 | 7.317 |
| Cash | - | - | 2.257 | 4.265 | 1.111 | 1.488 | 611 | 492 | 949 | 744 |
| Shareholders Funds | - | - | -4.211 | -4.048 | -16.362 | 673 | 1.083 | 1.779 | 4.703 | 2.381 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 30.895 | 43.620 | 52.086 | 25.157 | 23.116 | 26.150 | 62.704 | 62.220 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Ganoderma Pharm Srl